Chronic Lymphocytic Leukemia
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.
Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.
Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.
Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.
Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.
A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.
After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.
Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.
Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.
Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.
Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.
A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).
BCL2 Inhibitors in Previously Untreated CLL
ByWilliam Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University
Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.
ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL
ByWilliam Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University
An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.
Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.
Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.
Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.
Mitigating Toxicities Associated With BTK Inhibitors
ByWilliam Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University
A continuing discussion about the implications of toxicities with BTK inhibitors.
Safety and Efficacy of BTK Inhibitors in CLL
ByWilliam Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University
A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).
Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.
A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.
Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.
Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5